Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 258 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ACTOS/pioglitazone Clear all
Terminated Not applicable Interventional Results available

Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function

NCT00586261
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Pioglitazone, Placebo, Nitroglycerin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 17, 2026, 1:52 AM EDT
Completed Phase 2 Interventional

GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes

NCT00280865
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tesaglitazar, Pioglitazone, Dietary and Lifestyle Modification Counseling
Drug · Behavioral
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 50 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
90
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 87 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2006 · Synced Oct 17, 2026, 1:52 AM EDT
Completed Phase 4 Interventional

Molecular Mechanisms of Type 2 Diabetes Mellitus

NCT00816218
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Pioglitazone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 17, 2026, 1:52 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

NCT00203996
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions
continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp
Device · Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 17, 2026, 1:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation

NCT00470262
View directory record Official record
Conditions
Metabolic Syndrome X, Prediabetic State
Interventions
Fenofibrate 145mg PO QD, Pioglitazone 45 mg PO QD
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 17, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effects of Daily Administration of Pioglitazone on Brain Hemodynamics in Healthy Elderly Participants

NCT01456117
View directory record Official record
Conditions
Healthy
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
55 Years to 83 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Oct 17, 2026, 1:52 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

DPP-4 Inhibition and TZD for DM Prevention

NCT01006018
View directory record Official record
Conditions
Prediabetic State
Interventions
Sitagliptin + Pioglitazone PLACEBO, Sitagliptin + Pioglitazone, PLACEBO
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 17, 2026, 1:52 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.

NCT00708175
View directory record Official record
Conditions
Bone Metabolism
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
Up to 70 Years · Female only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
34
States / cities
Greenbrae, California • Los Banos, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 17, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Treating Nonalcoholic Steatohepatitis With Pioglitazone

NCT00062764
View directory record Official record
Conditions
Hepatitis
Interventions
Actos (Pioglitazone)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 17, 2026, 1:52 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke

NCT04123067
View directory record Official record
Conditions
Stroke, Acute, Hyperglycemia, Diabetes
Interventions
Pioglitazone 45 mg, Placebo oral tablet
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 17, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL

NCT00300365
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Pioglitazone, Placebo, Niacin ER, Aspirin
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 17, 2026, 1:52 AM EDT
Withdrawn Not applicable Interventional

Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients

NCT01695707
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pioglitazone, Placebo (for pioglitazone)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 17, 2026, 1:52 AM EDT
Terminated Phase 3 Interventional

Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

NCT00376181
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Pioglitazone and Azilsartan, Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
59
States / cities
Huntsville, Alabama • Tallassee, Alabama • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2010 · Synced Oct 17, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation

NCT01186250
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Oct 17, 2026, 1:52 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

A Study of Pleiotropic Pioglitazone Effects on the Alcoholic Lung (APPEAL Study)

NCT03060772
View directory record Official record
Conditions
Alcoholism
Interventions
Pioglitazone
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 17, 2026, 1:52 AM EDT
Terminated Phase 2 Interventional

Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

NCT00814372
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
MBX-102, Placebo, Actos, Metformin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Burbank, California • Los Angeles, California • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 17, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

NCT01210001
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, BI 10773
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
24
States / cities
Muscle Shoals, Alabama • Glendale, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 17, 2026, 1:52 AM EDT
Completed Not applicable Interventional Results available

Inflammation and Insulin Resistance in Rheumatoid Arthritis

NCT00763139
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 17, 2026, 1:52 AM EDT
Completed Phase 3 Interventional

Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia

NCT00331487
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Rosiglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
35 Years and older
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
67
States / cities
Anniston, Alabama • Birmingham, Alabama • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 17, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Pioglitazone on Platelet Function

NCT00861341
View directory record Official record
Conditions
Diabetes, Platelet Function, Healthy
Interventions
Aspirin, Pioglitazone
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 17, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

NCT03457597
View directory record Official record
Conditions
Healthy
Interventions
Midazolam hydrochloride, Metoprolol tartrate, Pioglitazone hydrochloride, Tolbutamide, Omeprazole, Relacorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 17, 2026, 1:52 AM EDT
Completed Phase 3 Interventional

Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes

NCT00097279
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, pioglitazone, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
73
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 17, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects

NCT01489943
View directory record Official record
Conditions
Crohn's Disease
Interventions
GSK1605786 500 mg, Midazolam 3 mg, Pioglitazone 15 mg, Omeprazole 40 mg, Rosuvastatin 10 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 17, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI)

NCT00736996
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Pioglitazone, Placebo, Endurance Exercise Training
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 15, 2016 · Synced Oct 17, 2026, 1:52 AM EDT